Search results for "Dilator"

showing 10 items of 273 documents

Late Breaking Abstract - Dose-ranging study of mepolizumab in eosinophilic COPD

2018

Background: Patients with eosinophilic COPD & frequent exacerbations may benefit from mepolizumab (MEP) treatment. Objective: Assess efficacy & safety of 2 MEP doses vs placebo (PBO) in COPD with blood eosinophils ≥150 cells/µL [screening] or ≥300 cells/µL [prior yr], history of ≥2 moderate/≥1 severe exacerbations & ICS+≥2 bronchodilator maintenance therapies (ICS+MT). Methods: Phase III, randomised, PBO-controlled, double-blind, parallel-group trial (METREO); patients received SC MEP 100mg, MEP 300mg or PBO plus ICS+MT, every 4 wks for 52 wks. Primary endpoint: rate/yr of moderate (systemic corticosteroids/antibiotics)/severe(hospitalisation or death) exacerbations. Secondary endpoints inc…

education.field_of_studymedicine.medical_specialtyCOPDmedicine.drug_classbusiness.industryPopulationPlaceboDose-ranging studymedicine.diseaseGastroenterology03 medical and health sciences0302 clinical medicineBronchodilatorInternal medicineEosinophilicClinical endpointmedicine030212 general & internal medicineeducationbusinessMepolizumab030217 neurology & neurosurgerymedicine.drugClinical Problems
researchProduct

Pentaerithrityl tetranitrate improves angiotensin II induced vascular dysfunction via induction of heme oxygenase-1

2010

The organic nitrate pentaerythritol tetranitrate is devoid of nitrate tolerance, which has been attributed to the induction of the antioxidant enzyme heme oxygenase (HO)-1. With the present study, we tested whether chronic treatment with pentaerythritol tetranitrate can improve angiotensin II–induced vascular oxidative stress and dysfunction. In contrast to isosorbide-5 mononitrate (75 mg/kg per day for 7 days), treatment with pentaerythritol tetranitrate (15 mg/kg per day for 7 days) improved the impaired endothelial and smooth muscle function and normalized vascular and cardiac reactive oxygen species production (mitochondria, NADPH oxidase activity, and uncoupled endothelial NO synthase)…

medicine.medical_specialtyAntioxidantNitric Oxide Synthase Type IIImedicine.medical_treatmentVasodilator AgentsBlotting WesternFluorescent Antibody TechniquePentaerythritol tetranitratemedicine.disease_causePentaerythritolArticlechemistry.chemical_compoundInternal medicineRats Inbred SHRInternal MedicinemedicineAnimalsPentaerythritol TetranitrateEndothelial dysfunctionchemistry.chemical_classificationReactive oxygen speciesAnalysis of VarianceAngiotensin IImedicine.diseaseAngiotensin IIMitochondriaRatsHeme oxygenaseOxidative StressEndocrinologychemistryHeminEndothelium VascularReactive Oxygen SpeciesOxidative stressHeme Oxygenase-1
researchProduct

Myocardial blood flow quantification for evaluation of coronary artery disease by computed tomography

2017

During the last decade coronary computed tomography angiography (CTA) has become the preeminent non-invasive imaging modality to detect coronary artery disease (CAD) with high accuracy. However, CTA has a limited value in assessing the hemodynamic significance of a given stenosis due to a modest specificity and positive predictive value. In recent years, different CT techniques for detecting myocardial ischemia have emerged, such as CT-derived fractional flow reserve (FFR-CT), transluminal attenuation gradient (TAG), and myocardial CT perfusion (CTP) imaging. Myocardial CTP imaging can be performed with a single static scan during first pass of the contrast agent, with monoenergetic or dual…

medicine.medical_specialtyCardiac computed tomographyMyocardial blood flow quantificationPerfusion scanningFractional flow reserveReview Article030204 cardiovascular system & hematology030218 nuclear medicine & medical imagingCoronary artery disease03 medical and health sciencesMyocardial perfusion imaging0302 clinical medicineStress imagingInternal medicinemedicinemedicine.diagnostic_testbusiness.industryMyocardial perfusion imagingmedicine.diseaseRegadenosonDipyridamoleCoronary artery disease (CAD)StenosisCardiologyRadiologyCoronary vasodilatorbusinessCardiology and Cardiovascular MedicineSettore MED/36 - Diagnostica Per Immagini E Radioterapiamedicine.drug
researchProduct

Levosimendan in the treatment of patients with acute cardiac conditions: an expert opinion of the Association of Intensive Cardiac Care of the Polish…

2020

Levosimendan is a new inodilator which involves 3 main mechanisms: increases the calcium sensitivity of cardiomyocytes, acts as a vasodilator due to the opening of potassium channels, and has a cardioprotective effect. Levosimendan is mainly used in the treatment of acute decompensated heart failure (class IIb recommendation according to the European Society of Cardiology guidelines). However, numerous clinical trials indicate the validity of repeated infusions of levosimendan in patients with stable heart failure as a bridge therapy to heart transplantation, and in patients with accompanying right ventricular heart failure and pulmonary hypertension. Due to the complex mechanism of action,…

medicine.medical_specialtyCardiotonic AgentsAcute decompensated heart failureinotropic agentsacute heart failuremedicine.medical_treatment030204 cardiovascular system & hematologylevosimendan03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansinodilatorAdverse effectExpert TestimonySimendanHeart FailureHeart transplantationbusiness.industryHydrazonesLevosimendanmedicine.diseasePulmonary hypertensionCardiac surgeryPyridazinesClinical trialHeart failurechronic advanced systolic heart failureCardiologyPolandCardiology and Cardiovascular Medicinebusinessmedicine.drugKardiologia Polska
researchProduct

Special Considerations for Antihypertensive Agents in Dialysis Patients

2010

Hypertension is present in most patients with end-stage renal disease and likely contributes to the premature cardiovascular disease in dialysis patients. Previous practice guidelines have recommended that, in patients on chronic dialysis, blood pressure (BP) should be reduced below 130/80 mm Hg. This is based on opinions but not strong evidence, since no concrete information exists about which BP values should be the parameter to follow and which should be the target BP values. The majority of the antihypertensive agents can be used in this population, but the pharmacokinetics altered by the impaired kidney function and dialyzability influence the appropriate dosage as well as the time and…

medicine.medical_specialtyCardiotonic AgentsHypertension RenalCombination therapyMetabolic Clearance Ratemedicine.drug_classVasodilator Agentsmedicine.medical_treatmentAdrenergic beta-AntagonistsPopulationAngiotensin-Converting Enzyme InhibitorsCardiotonic AgentsRenal DialysisInternal medicinemedicineHumansDrug InteractionsDiureticseducationAntihypertensive drugAntihypertensive AgentsDialysisRandomized Controlled Trials as Topiceducation.field_of_studybusiness.industryHematologyGeneral MedicineCalcium Channel Blockersmedicine.diseaseEndocrinologyBlood pressureCardiovascular DiseasesNephrologyPractice Guidelines as TopicPolypharmacyKidney Failure ChronicDrug Therapy CombinationHemodialysisbusinessAngiotensin II Type 1 Receptor BlockersKidney diseaseBlood Purification
researchProduct

Fluticasone propionate/formoterol: a fixed-combination therapy with flexible dosage.

2014

International guidelines describe asthma control as the main outcome of asthma management. Prevention of symptoms, improved quality of life, and reduction of exacerbations are the main components, consequently decreasing health care costs. However, many of these objectives remain unmet in real life: several surveys show that a large proportion of asthmatic patients are not well controlled despite the efficacy of current available treatment. Several randomized controlled clinical trials indicate that combining inhaled corticosteroids and long-acting β2-agonists, by means of a single inhaler, greatly improves the management of the disease. The results of 9 multicenter phase III clinical studi…

medicine.medical_specialtyCombination therapyAsthma exacerbationSettore MED/10 - Malattie dell'Apparato RespiratorioSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionateAsthma control; Asthma exacerbations; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhalerAsthma controlFluticasone propionate/formoterolForced Expiratory VolumeFormoterol FumarateInternal MedicineMedicineHumansAnti-Asthmatic AgentsAsthma exacerbationsParticle SizeIntensive care medicineAsthmaFluticasonebusiness.industryInhalerNebulizers and VaporizersFixed-combination therapyAsthma control; Asthma exacerbations; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhaler; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Drug Combinations; Ethanolamines; Fluticasone; Forced Expiratory Volume; Formoterol Fumarate; Humans; Nebulizers and Vaporizers; Particle Size; Quality of Life; Treatment Outcomemedicine.diseaseSingle-aerosol inhalerAsthmaBronchodilator AgentsAndrostadienesDrug CombinationsTreatment OutcomeTolerabilityAsthma control Asthma exacerbations Fixed-combination therapy Fluticasone propionate/formoterol Single-aerosol inhalerEthanolaminesAnesthesiaAsthma exacerbations; Asthma control; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhalerQuality of LifeFluticasoneFormoterol FumarateFormoterolbusinessmedicine.drugEuropean journal of internal medicine
researchProduct

Role of Nitrates for the Therapy of Coronary Artery Disease Patients in the Years beyond 2000

1999

Vasodilator therapy with nitrates has been used for almost a century to bring relief to patients suffering from angina. The acute anti-ischemic effects of nitro-vasodilators for the treatment and prevention of anginal attacks is unquestioned. In addition, nitrates are administered in order to reduce symptomatic and silent ischemic episodes, in patients with proven coronary heart disease who exert ST segment alterations on Holter monitoring. The reduction in total ischemic burden may result in an improved prognosis with regard to infarct prevention and possible prevention of deterioration of left ventricular function due to repetitive episodes of myocardial ischemia. In patients with unstabl…

medicine.medical_specialtyCombination therapyVasodilator AgentsMyocardial InfarctionCoronary DiseaseAngina PectorisAnginaCoronary artery diseaseInternal medicinemedicineHumansMyocardial infarctionPharmacologyClinical Trials as TopicNitratesbusiness.industryUnstable anginaDrug Tolerancemedicine.diseasePreloadHeart failureACE inhibitorCardiologybusinessCardiology and Cardiovascular MedicineForecastingmedicine.drugJournal of Cardiovascular Pharmacology
researchProduct

Pharmacological Management of Elderly Patients with Asthma–Chronic Obstructive Pulmonary Disease Overlap Syndrome: Room for Speculation?

2016

Asthma and chronic obstructive pulmonary disease (COPD) are two distinct diseases that share a condition of chronic inflammation of the airways and bronchial obstruction. In clinical settings, it is not rare to come across patients who present with clinical and functional features of both diseases, posing a diagnostic dilemma. The overlap condition has been termed asthma–COPD overlap syndrome (ACOS), and mainly occurs in individuals with long-standing asthma, especially if they are also current or former smokers. Patients with ACOS have poorer health-related quality of life and a higher exacerbation rate than subjects with asthma or COPD alone. Whether ACOS is a distinct nosological entity …

medicine.medical_specialtyExacerbationPopulationSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicinePharmacotherapyAdrenal Cortex HormonesAdministration InhalationPrevalencemedicineHumansPharmacology (medical)030212 general & internal medicineIntensive care medicineeducationAgedAsthmaCOPDeducation.field_of_studyLungbusiness.industryOverlap syndromemedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesmedicine.anatomical_structure030228 respiratory systemQuality of LifePhysical therapyDrug Therapy CombinationSalmeterolGeriatrics and Gerontologybusinessmedicine.drugDrugs & Aging
researchProduct

Non-Hemodynamic Effects of Organic Nitrates and the Distinctive Characteristics of Pentaerithrityl Tetranitrate

2009

Organic nitrates are among the oldest and yet most commonly employed drugs in the long-term therapy of coronary artery disease and congestive heart failure. While they have long been used in clinical practice, our understanding of their mechanism of action and side effects remains incomplete. For instance, recent findings provide evidence of previously unanticipated, non-hemodynamic properties that include potentially beneficial mechanisms (such as the induction of a protective phenotype that mimics ischemic preconditioning), but also toxic effects (such as endothelial and autonomic dysfunction, rebound angina, tolerance). To date, the most commonly employed organic nitrates are isosorbide …

medicine.medical_specialtyHeart DiseasesVasodilator AgentsIsosorbide DinitratePharmacologyDrug Administration ScheduleAnginaCoronary artery diseaseNitroglycerinmedicineIsosorbide mononitrateAnimalsHumansPentaerythritol TetranitratePharmacology (medical)NitroglycerinNitratesbusiness.industryDrug ToleranceGeneral Medicinemedicine.diseaseSurgeryEastern europeanOxidative StressHeart failureIschemic preconditioningIsosorbide dinitrateReactive Oxygen SpeciesCardiology and Cardiovascular Medicinebusinessmedicine.drugAmerican Journal of Cardiovascular Drugs
researchProduct

Treatment of pulmonary hypertension in patients undergoing cardiac surgery with cardiopulmonary bypass: a randomized, prospective, double-blind study

2006

Pulmonary hypertension can already be present in patients undergoing cardiac surgery or can be exacerbated by cardiopulmonary bypass. Postoperative treatment is still a challenge for physicians. The aim of this study was to evaluate the effects of inhaled prostacyclin (iPGI2) and nitric oxide (iNO) compared with those of intravenous vasodilators.This prospective, randomized, double-blind study included 58 patients affected by severe mitral valve stenosis and pulmonary hypertension with high pulmonary vascular resistance (250 dynes x s x cm(-5)) and a mean pulmonary artery pressure25 mmHg. All patients were monitored by central venous, radial arterial and Swan-Ganz catheters. Data were recor…

medicine.medical_specialtyHypertension PulmonaryHemodynamicsProstacyclinVasodilationNitric Oxidelaw.inventionDouble-Blind MethodRandomized controlled triallawInternal medicineAdministration InhalationCardiopulmonary bypassmedicineHumansMitral Valve StenosisProspective StudiesProspective cohort studyAntihypertensive AgentsAgedCardiopulmonary Bypassbusiness.industryfungiHemodynamicsfood and beveragesGeneral MedicineLength of StayMiddle Agedmedicine.diseaseEpoprostenolPulmonary hypertensionBronchodilator AgentsCardiac surgeryAnesthesiaCardiologyCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of Cardiovascular Medicine
researchProduct